- This event has passed.
ViaCyte and “The Human Trial”: curing type 1 diabetes
January 27, 2016 @ 1:00 pm - 2:00 pm
1pm PT, 4pm ET, 8pm GMTJoin us HERE at the time and date of the event
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goals of no immune suppression required, and a reduced risk of hypoglycemia and diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
Paul K. Laikind, Ph.D. is President, CEO and a member of the Board of ViaCyte, Inc. He has over 28 years of leadership experience in the biotechnology and life sciences industry in San Diego. Dr. Laikind holds a B.S. in Biochemistry from the University of California, Davis, and a Ph.D. in biochemistry from the University of California, San Diego.
Vox Pop Films
Vox Pop Films is a full-service production company based in Los Angeles. Prior to forming Vox Pop Films in New York City in 2008, Director Lisa Hepner and Director / DP Guy Mossman built careers as successful documentarians. Our film and commercial work has been internationally recognized from Sundance to Seoul.
Lisa Hepner currently runs Vox Pop Films with her partner, Guy Mossman. For the past 21 years, Lisa has produced a variety of films and programs for Sony Pictures Classics, HBO, A&E, PBS, Lifetime, Discovery, MTV, TLC and the CBC. In 2003, she directed Peace by Peace: Women on the Frontlines that marked her documentary directorial debut. Lisa has lived with Type 1 diabetes for 25 years.
Here’s a recording of the live event in case you missed it.
Thanks for tuning in!